Marinus Pharmaceuticals, Inc. Class Action Lawsuit - MRNS

The filed complaint alleges that Marinus Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants understated the risk of failure to meet the early-stopping criteria in the Randomized Therapy in Status Epilepticus Trial (RAISE); (2) defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

In order to be eligible to join the MRNS class action lawsuit, you must have incurred a loss on shares of Marinus purchased during the class period listed above.

If you suffered a loss in Marinus during the relevant time frame or pursuant to the relevant offering(s), you have until August 5, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.